Search ARM

GICELL is developing safe, effective, and affordable immune cell therapies with the proprietary ancillary protein (AP) platform to overcome the limitations of existing cell therapies such as limited efficacy, high prices, and safety issues. Headquartered in Seoul, Korea, we have offices, R&D centers, and cell and protein manufacturing facilities and capabilities. We offer both NK and T cell products for the treatment of solid and liquid cancers and Treg cell product for the treatment of auto-immune disease. So far, we have secured approximately 100 million US dollars in financing. IND for our off-the-shelf allogeneic NK cell is anticipated in 2022.
Contact GI Cell, Inc
Visit Website